Distribution agreement with BTL Zdravotnická Technika, A.S.

The Management Board of Nestmedic S.A., with its registered office in Warsaw, _further referred to as the “Company”, “Issuer”_, in pursuit of the objectives set out in the updated strategy of the Issuer’s capital group for 2018-2023, communicated to the public on 6 October 2020, by ESPI current report No. 35/2020, i.e. in particular to build cooperation and relations with foreign partners and distribution network, announces that on 03 November 2022, a bilateral distribution agreement _further referred to as the “Agreement”_ was signed with BTL Zdravotnická Technika, A.S. _ hereinafter the “Distributor”_.

The subject matter of the Agreement is the granting to the Distributor of the right to distribute the PREGNABIT PRO equipment specified in the Agreement and the licence to use the PREGNABIT CLOUD Platform _ hereinafter “Products” _ in the agreed territory covering the Czech Republic , as well as the right to offer and provide to end users – customers or third parties operating in the aforementioned territory, such as hospitals and other treatment centres – services concerning the Products, including in particular implementation and maintenance services, as well as training concerning the Products, under the terms and conditions specified in the Agreement.
The Distributor will perform all activities under the Agreement in its own name and on its own account as an independent entity. The Issuer will not act as a party to agreements between third parties and the Distributor. The Agreement provides that the Distributor will also undertake the agreed marketing activities, inter alia, by promoting the sale of the Products in the territory indicated above in order to make the best use of the market potential of the Products.

The Agreement was concluded for a fixed period of two  years with the possibility of its extension.

The Issuer considered the above information important due to the fact that gaining a foreign partner opens up the possibility of promoting and implementing the Issuer’s Products on new markets, which in the Management Board’s opinion may have a significant impact on the Issuer’s and its capital group’s financial situation in the future.